Last reviewed · How we verify

NCT05148182: MEAL

Metabolomics Characterization of Biomarkers of ASCVD and Prediction Model

Status unknown Last updated 8 December 2021
What this trial tests

trial in Atherosclerosis in 1,869 participants. Status unknown.

Timeline
15 December 2021
Primary endpoint
15 December 2024
15 December 2024

Quick facts

Lead sponsorShanghai 10th People's Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,869
Start date15 December 2021
Primary completion15 December 2024
Estimated completion15 December 2024
Sites2 locations across China

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 18 to 90, any sex, with Atherosclerosis or Prediction Model. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Describe the risk factors and metabonomics characteristics of atherosclerotic cardiovascular disease in Chinese patients. 2. Establish accurate prediction model of atherosclerotic heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atherosclerosis

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05148182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing